| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Original Studies |
Third Department of Internal Medicine, Mie University School of Medicine, Tsu, Mie 514-8507, Japan
Address all correspondence and requests for reprints to Dr. Yutaka Yano, Third Department of Internal Medicine, Mie University School of Medicine, Edobashi 2174, Tsu, Mie 514-8507, Japan. E-mail: yanoyuta{at}clin.medic.mie-u.ac.jp
Brain natriuretic peptide (BNP), a member of the natriuretic peptide family, is produced and released from cardiac ventricles. BNP regulates the body fluid volume, blood pressure, and vascular tones through the A-type guanylate cyclase-coupled receptor. The presence of renal dysfunction in patients with diabetes affects the plasma levels of atrial natriuretic peptide (ANP). In the present study, we investigated the plasma levels of BNP and ANP and their relationship in normotensive diabetic patients with normoalbuminuria and microalbuminuria. Forty-seven normotensive lean noninsulin-dependent diabetic patients (31 with normoalbuminuria, 16 with microalbuminuria), with normal cardiac function, and 30 age-matched control subjects were enrolled in this study. The plasma levels of BNP in diabetic patients with microalbuminuria were significantly higher than those in diabetic patients with normoalbuminuria (16.7 ± 2.4 vs. 9.6 ± 1.3 pg/mL, P < 0.01) or normal subjects (16.7 ± 2.4 vs. 7.0 ± 0.6 pg/mL, P < 0.01). There was a significant positive correlation between plasma BNP levels and urinary albumin excretion rate in all diabetic patients (r = 0.58, P < 0.0001). There was also a significantly positive correlation between plasma BNP and ANP levels in diabetic patients (r = 0.62, P < 0.0001). The increased plasma level of BNP in patients with microalbuminuria and its significant correlation with urinary albumin excretion rate suggest that the elevated circulating levels of BNP are caused by the presence of diabetic nephropathy. Down-regulation of A-type guanylate cyclase-coupled receptor of renal tubules may explain the increased plasma levels of both BNP and ANP in normotensive diabetic patients with microalbuminuria.
This article has been cited by other articles:
![]() |
P. Symeonides, S. Koulouris, E. Vratsista, K. Triantafyllou, G. Ioannidis, N. Thalassinos, and D. Katritsis Both ramipril and telmisartan reverse indices of early diabetic cardiomyopathy: A comparative study Eur J Echocardiogr, December 1, 2007; 8(6): 480 - 486. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Ingelsson, J. Sundstrom, L. Lind, U. Riserus, A. Larsson, S. Basu, and J. Arnlov Low-grade albuminuria and the incidence of heart failure in a community-based cohort of elderly men Eur. Heart J., July 2, 2007; 28(14): 1739 - 1745. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. J. Wang, M. G. Larson, M. J. Keyes, D. Levy, E. J. Benjamin, and R. S. Vasan Association of Plasma Natriuretic Peptide Levels With Metabolic Risk Factors in Ambulatory Individuals Circulation, March 20, 2007; 115(11): 1345 - 1353. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Kragelund, I. Gustafsson, T. Omland, B. Gronning, L. Kober, J. Faber, S. Strande, R. Steffensen, and P. Hildebrandt Prognostic Value of NH2-Terminal Pro B-Type Natriuretic Peptide in Patients With Diabetes and Stable Coronary Heart Disease. Diabetes Care, June 1, 2006; 29(6): 1411 - 1413. [Full Text] [PDF] |
||||
![]() |
M. H. Olsen, T. W. Hansen, M. K. Christensen, F. Gustafsson, S. Rasmussen, K. Wachtell, K. Borch-Johnsen, H. Ibsen, T. Jorgensen, and P. Hildebrandt N-Terminal Pro Brain Natriuretic Peptide Is Inversely Related to Metabolic Cardiovascular Risk Factors and the Metabolic Syndrome Hypertension, October 1, 2005; 46(4): 660 - 666. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. H.B. Wu, T. Omland, P. Duc, J. McCord, R. M. Nowak, J. E. Hollander, H. C. Herrmann, P. G. Steg, C. Wold Knudsen, A. B. Storrow, et al. The Effect of Diabetes on B-Type Natriuretic Peptide Concentrations in Patients With Acute Dyspnea: An analysis from the Breathing Not Properly Multinational Study Diabetes Care, October 1, 2004; 27(10): 2398 - 2404. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Magnusson, O. Melander, B. Israelsson, A. Grubb, L. Groop, and S. Jovinge Elevated Plasma Levels of Nt-proBNP in Patients With Type 2 Diabetes Without Overt Cardiovascular Disease Diabetes Care, August 1, 2004; 27(8): 1929 - 1935. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. J. Wang, M. G. Larson, D. Levy, E. J. Benjamin, E. P. Leip, P. W.F. Wilson, and R. S. Vasan Impact of Obesity on Plasma Natriuretic Peptide Levels Circulation, February 10, 2004; 109(5): 594 - 600. [Abstract] [Full Text] [PDF] |
||||
![]() |
I Raymond, B A Groenning, P R Hildebrandt, J C Nilsson, M Baumann, J Trawinski, and F Pedersen The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population Heart, July 1, 2003; 89(7): 745 - 751. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. N. Chan and S. J. Hurel Brain Natriuretic Peptide as a Potential Marker of Diastolic Dysfunction in Type 2 Diabetes Diabetes Care, November 1, 2001; 24(11): 2019 - 2020. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |